・CEO Richard Adcock said the long-delayed Dunkirk manufacturing site is now “all systems go” after a unanimous resolution at a CCIDA board meeting. ・The Dunkirk facility is expected to serve as a key ...

ANKTIVA ® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio’s 400,000 square foot GMP fill-finish facility in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min ImmunityBio plans to use the ...

Dunkirk's state-of-the-art facility is expected to play a significant role in the production of a new cancer-fighting drug developed by ImmunityBio Inc. On Tuesday, the company announced in a news ...

ImmunityBio races to meet NY production deadlines, battles short sellers and class-action lawsuits, while Anktiva sales rise in its strongest quarter. The clock is ticking on multiple fronts for ...

ImmunityBio Inc. probably won't ramp up hiring at its Dunkirk plant for a couple years, the city's planning and development director said last week. Vince DeJoy gave a mostly upbeat update about the ...

DUNKIRK, N.Y. — ImmunityBio has filed a WARN notice with the New York state Department of Labor for two layoffs at its plant in Dunkirk. According to the notice, the California-based biopharmaceutical ...

ImmunityBio reports $44.2M in Q1 revenue but faces a securities lawsuit over FDA warning and a critical deadline for its Dunkirk facility, while advancing its bladder cancer trial. ImmunityBio finds ...

It’s been an up-and-down several years at a state-funded, $200 million drug manufacturing plant in Dunkirk, a facility that – to date – still has not actually manufactured a drug.

ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth and significant market share in NMIBC. IBRX’s pipeline is robust, with multiple Phase 1-3 trials ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for “fill finish” (filling vials and ...